The total return over the past 12 months is -8.63% vs. +16.94% for the S&P 500. So far it's up -46.69% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (8.63%) | (27.86%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (8.63%) | (27.86%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | (94.10%) | (52.38%) | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Entrada Therapeutics, Inc. (TRDA)
| Year | Start price | End price | TRDA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $10.28 | $5.48 | (46.69%) | +14.51% | (61.20%) |
| 2025 | $17.29 | $10.28 | (40.54%) | +17.72% | (58.26%) |
| 2024 | $15.09 | $17.29 | +14.58% | +24.89% | (10.31%) |
| 2023 | $13.52 | $15.09 | +11.61% | +26.19% | (14.58%) |
| 2022 | $17.12 | $13.52 | (21.03%) | (18.17%) | (2.86%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
